The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit.

In this issue, we look at the complex relationship between bullying and suicidality and offer a range of ideas on how to help your patients with this all-too-common problem, both in the office and in advocating for your patients, with resources to boot.

Do antidepressants actually cause children to be suicidal? If so, how do we detect it, and what should we do about it? In this article, we’ll give you a brief review of the most recent findings on antidepressant-induced suicidality (AIS) in children and adolescents, and then move on to some practical tips for how to evaluate and prevent this problem.

The issue of emergent suicidal thinking has weighed on us since the 2004 black box warning—amplified by the re-analysis of the now infamous study 329, which found the emergence of previously under-reported suicidal thinking. How do we offer hope for effective use of medication while balancing the potential risks? Dr. Danella Hafeman has made a close study of it all and sheds light on the problem.

Recently, CCPR presented the following hypothetical case to leading child and adolescent development authority Calvin Colarusso, MD, for his advice on how to help a young man presenting with a possible major depressive disorder (MDD).

Managing childhood anxiety can sometimes leave clinicians in a quandary. There is a paucity of evidence comparing different treatment approaches, and current guidelines on the subject are old and make inconsistent recommendations.

In 2015, the FDA approved Dyanavel XR (amphetamine extended release oral suspension), which was the first long-acting liquid version of amphetamine on the market. To provide some context, Quillivant XR, a long-action liquid methylphenidate formulation, was approved in 2012 and appears to be fairly popular for kids who can’t or won’t swallow pills. Seeing a market opportunity, Tris Pharmaceuticals developed Dyanavel XR and funded a placebo-controlled trial that was successful enough to gain FDA approval. Recently, this study was published, and some readers might be curious to look at the quality of the data.

One of our biggest in-office challenges is how to enhance teen resilience, the process of adapting to and recovering from stressful life experiences. Some neuroscientists hypothesize that resilience is related to the limbic system, which plays a vital role in emotion processing, motivation, and learning.